- Operating Expenses Decline 4% Year-to-Date
- Balance Sheet Strengthens and Working Capital Improves by 14.7%
IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ:BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025.
Key Highlights:
| 1. | Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein | |
| During the second quarter, Biomerica entered into a marketing services agreement with Henry Schein to support the commercialization of the Company’s inFoods® IBS test in the United States. In addition, inFoods® IBS was featured in a Henry Schein publication highlighting a precision-based approach to the management of Irritable Bowel Syndrome. Together, these initiatives expand awareness of inFoods® IBS among healthcare providers and support broader adoption of the test in clinical practice. | ||
| 2. | Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes | |
| The launch of its inFoods® IBS Trigger Food Navigator, a comprehensive AI-backed digital companion tool designed to improve patient dietary compliance and treatment success for individuals with Irritable Bowel Syndrome (IBS). The inFoods® IBS test identifies, on average, two to four specific foods that trigger a patient’s IBS symptoms, leading to a simple, highly targeted and actionable dietary plan. The new AI-backed Trigger Food Navigator builds on this approach by making it even easier for patients to follow their personalized dietary plan through smart meal suggestions, ingredient substitutions, and simplified meal planning tools. | ||
| Subsequent to Quarter End | ||
| 3. | CMS Establishes National Medicare Payment Rate for inFoods® IBS Test | |
| Subsequent to the quarter-ended November 30, 2025, the Centers for Medicare & Medicaid Services (CMS) established a national Medicare payment rate of $300 for Biomerica’s inFoods® IBS test, effective January 1, 2026. This milestone provides reimbursement clarity and represents an important step toward expanding patient access to the inFoods® IBS product through the Medicare system. | ||
| 4. | Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio | |
| Subsequent to quarter end, the Egyptian Drug Authority authorized Biomerica’s complete screening test portfolio. This regulatory approval expands access to the Company’s rapid diagnostic solutions in Egypt and supports continued international expansion of Biomerica’s diagnostic products. | ||
Management Commentary
Zack Irani, CEO said, “We are executing a deliberate strategic pivot from legacy, lower-margin products to higher-value, higher-margin diagnostic-guided therapy products. The current revenue softness reflects this transition, not fundamental business deterioration. With our fixed cost structure largely in place, we believe incremental revenue from inFoods® IBS and new partnerships such as Henry Schein as well as hp+detect™ opportunities should drive significant margin expansion. Additionally, our contract development and manufacturing organization (CDMO) expansion leverages existing infrastructure to generate higher-margin revenue while diversifying our revenue base.”
“While second quarter revenue reflected expected variability across our established product lines, Biomerica continued to strengthen its financial foundation through successful capital raising activities and disciplined cost management,” said Gary Lu, CFO of Biomerica. “Earlier in the fiscal year, the Company also received approximately $1.10 million in Employee Retention Credit (ERC) refunds, which, together with our financing initiatives, contributed to a $457,000 year-to-date improvement in working capital and an increase in our cash position to $2.5 million. As we advance key programs from development into commercialization, we are prudently reallocating resources, which resulted in a 27% reduction in research and development expenses, while continuing to invest in the commercial launch of high-value diagnostic programs, including inFoods® IBS and hp+detect™. We maintain access to additional capital through our existing shelf registration to support future growth initiatives.”
Second Quarter and Year-to-Date Fiscal 2026 Financial Results
Net sales for the second quarter of fiscal 2026 were $1.21 million, compared to $1.64 million in the prior year quarter. The decrease primarily reflects the absence of large initial distributor stocking …